|
1
|
Fang C, Zhu T, Zhang P, Xia L and Sun C:
Risk factors of neurosurgical site infection after craniotomy: A
systematic review and meta-analysis. Am J Infect Control.
45:e123–e134. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Korinek AM, Baugnon T, Golmard JL, van
Effenterre R, Coriat P and Puybasset L: Risk factors for adult
nosocomial meningitis after craniotomy: Role of antibiotic
prophylaxis. Neurosurgery. 62 (Suppl 2):S532–S539. 2008.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Karaiskos I, Galani L, Baziaka F and
Giamarellou H: Intraventricular and intrathecal colistin as the
last therapeutic resort for the treatment of multidrug-resistant
and extensively drug-resistant Acinetobacter baumannii
ventriculitis and meningitis: A literature review. Int J Antimicrob
Agents. 41:499–508. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Huttova M, Freybergh PF, Rudinsky B,
Sramka M, Kisac P, Bauer F and Ondrusova A: Postsurgical meningitis
caused by Acinetobacter baumannii associated with high mortality.
Neuro Endocrinol Lett. 28 (Suppl 2):S15–S16. 2007.PubMed/NCBI
|
|
5
|
Metan G, Alp E, Aygen B and Sumerkan B:
Acinetobacter baumannii meningitis in post-neurosurgical patients:
Clinical outcome and impact of carbapenem resistance. J Antimicrob
Chemother. 60:197–199. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ranjbar R and Alam M: Antimicrobial
Resistance Collaborators (2022). Global burden of bacterial
antimicrobial resistance in 2019: A systematic analysis. Evid Based
Nurs: Jul 27, 2023 (Epub ahead of print).
|
|
7
|
Ayoub Moubareck C and Hammoudi Halat D:
Insights into Acinetobacter baumannii: A review of microbiological,
virulence, and resistance traits in a threatening nosocomial
pathogen. Antibiotics (Basel). 9(119)2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ibrahim S, Al-Saryi N, Al-Kadmy IMS and
Aziz SN: Multidrug-resistant Acinetobacter baumannii as an emerging
concern in hospitals. Mol Biol Rep. 48:6987–6998. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tokur ME, Korkmaz P, Alkan S, Yıldız E,
Arık Ö, Renders DP and Balcı C: Mortality predictors on the day of
healthcare-associated Acinetobacter baumanni bacteremia in
intensive care unit. J Infect Dev Ctries. 16:1473–1481.
2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ibrahim ME: Prevalence of Acinetobacter
baumannii in Saudi Arabia: Risk factors, antimicrobial resistance
patterns and mechanisms of carbapenem resistance. Ann Clin
Microbiol Antimicrob. 18(1)2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhu Y, Zhang X, Wang Y, Tao Y, Shao X, Li
Y and Li W: Insight into carbapenem resistance and virulence of
Acinetobacter baumannii from a children's medical centre in eastern
China. Ann Clin Microbiol Antimicrob. 21(47)2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Mohajeri P, Sharbati S, Farahani A and
Rezaei Z: Evaluate the frequency distribution of nonadhesive
virulence factors in carbapenemase-producing Acinetobacter
baumannii isolated from clinical samples in Kermanshah. J Nat Sci
Biol Med. 7:58–61. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Nau R, Seele J, Djukic M and Eiffert H:
Pharmacokinetics and pharmacodynamics of antibiotics in central
nervous system infections. Curr Opin Infect Dis. 31:57–68.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nau R, Sörgel F and Eiffert H: Penetration
of drugs through the blood-cerebrospinal fluid/blood-brain barrier
for treatment of central nervous system infections. Clin Microbiol
Rev. 23:858–883. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
De Bonis P, Lofrese G, Scoppettuolo G,
Spanu T, Cultrera R, Labonia M, Cavallo MA, Mangiola A, Anile C and
Pompucci A: Intraventricular versus intravenous colistin for the
treatment of extensively drug resistant Acinetobacter baumannii
meningitis. Eur J Neurol. 23:68–75. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mohajeri P, Farahani A, Feizabadi MM and
Norozi B: Clonal evolution multi-drug resistant Acinetobacter
baumannii by pulsed-field gel electrophoresis. Indian J Med
Microbiol. 33:87–91. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Tsuji BT, Pogue JM, Zavascki AP, Paul M,
Daikos GL, Forrest A, Giacobbe DR, Viscoli C, Giamarellou H,
Karaiskos I, et al: International Consensus Guidelines for the
Optimal Use of the Polymyxins: Endorsed by the American College of
Clinical Pharmacy (ACCP), European Society of Clinical Microbiology
and Infectious Diseases (ESCMID), Infectious Diseases Society of
America (IDSA), International Society for Anti-infective
Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and
Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy.
39:10–39. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Huang Q, Zhang X, Jia A, Huang Q, Jiang Y
and Xie L: The pharmacokinetics/pharmacodynamics and neurotoxicity
of tigecycline intraventricular injection for the treatment of
extensively drug-resistant acinetobacter baumannii intracranial
infection. Infect Drug Resist. 15:4809–4817. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Fang YQ, Zhan RC, Jia W, Zhang BQ and Wang
JJ: A case report of intraventricular tigecycline therapy for
intracranial infection with extremely drug resistant Acinetobacter
baumannii. Medicine (Baltimore). 96(e7703)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li LM, Zheng WJ and Shi SW: Spinal
arachnoiditis followed by intrathecal tigecycline therapy for
central nervous system infection by extremely drug-resistant
Acinetobacter baumannii. J Int Med Res.
48(300060520920405)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Deng ZW, Wang J, Qiu CF, Yang Y, Shi ZH
and Zhou JL: A case report of intraventricular and intrathecal
tigecycline infusions for an extensively drug-resistant
intracranial Acinetobacter baumannii infection. Medicine
(Baltimore). 98(e15139)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Rodvold KA, Gotfried MH, Cwik M,
Korth-Bradley JM, Dukart G and Ellis-Grosse EJ: Serum, tissue and
body fluid concentrations of tigecycline after a single 100 mg
dose. J Antimicrob Chemother. 58:1221–1229. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ray L, Levasseur K, Nicolau DP and Scheetz
MH: Cerebral spinal fluid penetration of tigecycline in a patient
with Acinetobacter baumannii cerebritis. Ann Pharmacother.
44:582–586. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pan S, Huang X, Wang Y, Li L, Zhao C, Yao
Z, Cui W and Zhang G: Efficacy of intravenous plus
intrathecal/intracerebral ventricle injection of polymyxin B for
post-neurosurgical intracranial infections due to MDR/XDR
Acinectobacter baumannii: A retrospective cohort study. Antimicrob
Resist Infect Control. 7(8)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Abdallah M, Alsaleh H, Baradwan A,
Alfawares R, Alobaid A, Rasheed A and Soliman I: Intraventricular
tigecycline as a last resort therapy in a patient with
difficult-to-treat healthcare-associated acinetobacter baumannii
ventriculitis: A case report. SN Compr Clin Med. 2:1683–1687.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Teasdale G, Maas A, Lecky F, Manley G,
Stocchetti N and Murray G: The Glasgow Coma Scale at 40 years:
Standing the test of time. Lancet Neurol. 13:844–854.
2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Capuano B and Cone DC: An Analysis of the
Distribution of Glasgow Coma Scale Scores across Pan-Asian Trauma
Outcomes Study (PATOS) Regions. Prehosp Disaster Med: Feb 14, 2022
(Epub ahead of print).
|
|
28
|
Institute CALS. Performance standards for
antimicrobial susceptibility testing. Clin Microbiol Newsletter.
23:M100–M111. 2019.
|
|
29
|
Peleg AY, Seifert H and Paterson DL:
Acinetobacter baumannii: Emergence of a successful pathogen. Clin
Microbiol Rev. 21:538–582. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fishbain J and Peleg AY: Treatment of
Acinetobacter infections. Clin Infect Dis. 51:79–84.
2010.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Ma MY, Xu J, Yu N and Huang GM: Analysis
of drug resistance of Acinetobacter baumannii and its related
factors in ICU. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 25:686–689.
2013.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
32
|
Spellberg B and Rex JH: The value of
single-pathogen antibacterial agents. Nat Rev Drug Discov.
12(963)2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Inchai J, Pothirat C, Bumroongkit C,
Limsukon A, Khositsakulchai W and Liwsrisakun C: Prognostic factors
associated with mortality of drug-resistant Acinetobacter baumannii
ventilator-associated pneumonia. J Intensive Care.
3(9)2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Uwingabiye J, Frikh M, Lemnouer A,
Bssaibis F, Belefquih B, Maleb A, Dahraoui S, Belyamani L, Bait A,
Haimeur C, et al: Acinetobacter infections prevalence and frequency
of the antibiotics resistance: Comparative study of intensive care
units versus other hospital units. Pan Afr Med J.
23(191)2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Willyard C: The drug-resistant bacteria
that pose the greatest health threats. Nature.
543(15)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Kim BN, Peleg AY, Lodise TP, Lipman J, Li
J, Nation R and Paterson DL: Management of meningitis due to
antibiotic-resistant Acinetobacter species. Lancet Infect Dis.
9:245–255. 2009.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gordon NC and Wareham DW:
Multidrug-resistant Acinetobacter baumannii: Mechanisms of
virulence and resistance. Int J Antimicrob Agents. 35:219–226.
2010.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Vila J and Pachón J: Acinetobacter
baumannii resistant to everything: what should we do? Clin
Microbiol Infect. 17:955–956. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Durante-Mangoni E and Zarrilli R: Global
spread of drug-resistant Acinetobacter baumannii: Molecular
epidemiology and management of antimicrobial resistance. Future
Microbiol. 6:407–422. 2011.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Pankey GA: Tigecycline. J Antimicrob
Chemother. 56:470–480. 2005.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Karageorgopoulos DE and Falagas ME:
Current control and treatment of multidrug-resistant Acinetobacter
baumannii infections. Lancet Infect Dis. 8:751–762. 2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Pallotto C, Fiorio M, D'Avolio A, Sgrelli
A, Baldelli F, Di Perri G and De Socio GV: Cerebrospinal fluid
penetration of tigecycline. Scand J Infect Dis. 46:69–72.
2014.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Long W, Yuan J, Liu J, Liu J, Wu M, Chen
X, Peng G, Wu C, Zhang C, Wang X, et al: Multidrug resistant brain
abscess due to acinetobacter baumannii ventriculitis cleared by
intraventricular and intravenous tigecycline therapy: A case report
and review of literature. Front Neurol. 9(518)2018.PubMed/NCBI View Article : Google Scholar
|
